Boehringer plugs in IBM-trained AI model to boost antibody drug discovery efforts

Boehringer Ingelheim will harness an artificial intelligence model trained in the computer labs of IBM as the German drugmaker becomes the latest Big Pharma to apply machine learning tools to its drug discovery efforts.